Transcode Therapeutics Inc Net Assets
Transcode Therapeutics Inc net assets. Based on the latest financial reports, Transcode Therapeutics Inc (RNAZ) has net assets worth $138.36 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($151.01 Million) and total liabilities ($12.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Transcode Therapeutics Inc net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $138.36 Million |
| % of Total Assets | 91.62% |
| Annual Growth Rate | N/A |
| 5-Year Change | -49.35% |
| 10-Year Change | N/A |
| Growth Volatility | 75.03 |
Net Assets of Transcode Therapeutics Inc (2018–2025)
Net assets of Transcode Therapeutics Inc from 2018 to 2025. This chart illustrates how Transcode Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Transcode Therapeutics Inc net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Transcode Therapeutics Inc (2018–2025)
The table below shows the annual net assets of Transcode Therapeutics Inc from 2018 to 2025. For live market cap and overall valuation, see RNAZ market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $10.34 Million | +611.98% |
| 2024-12-31 | $-2.02 Million | -223.03% |
| 2023-12-31 | $1.64 Million | -49.37% |
| 2022-12-31 | $3.24 Million | -84.12% |
| 2021-12-31 | $20.40 Million | +698.68% |
| 2020-12-31 | $-3.41 Million | -210.54% |
| 2019-12-31 | $-1.10 Million | -117.77% |
| 2018-12-31 | $-503.97K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Transcode Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9735221500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Transcode Therapeutics Inc Net Assets Breakdown (December 2025)
Transcode Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $92.00 | 0.00% |
| Other Components | $108.20 Million | 1046.86% |
| Total Equity | $10.34 Million | 100.00% |
Transcode Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Transcode Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TECIL Chemicals and Hydro Power Limited
NSE:TECILCHEM
|
$1.66 Million |
|
Golden Sun Education Group Ltd
NASDAQ:GSUN
|
$1.66 Million |
|
Haoxin Holdings Limited Class A Ordinary Shares
NASDAQ:HXHX
|
$1.66 Million |
|
TROC DE L'ILE SA
PA:MLTRO
|
$1.67 Million |
|
MOBA Network publ AB
ST:MOBA
|
$1.66 Million |
|
Hepion Pharmaceuticals Inc
NASDAQ:HEPA
|
$1.66 Million |
|
Vertical Explorations Inc
V:VERT
|
$1.66 Million |
|
Smtrack Bhd
KLSE:0169
|
$1.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Transcode Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -2,018,733 to 10,335,466, a change of 12,354,199.
- Net loss of 34,661,076 reduced equity.
- Dividend payments of 1,610,211,000 reduced retained earnings.
- New share issuances of 31,523,122 increased equity.
- Other factors increased equity by 1,625,703,153.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-34.66 Million | -335.36% |
| Dividends Paid | $1.61 Billion | -15579.47% |
| Share Issuances | $31.52 Million | +305.0% |
| Other Changes | $1.63 Billion | +15729.36% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Transcode Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.10x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-2621.96 | $1.57 | x |
| 2019-12-31 | $-171.30 | $1.57 | x |
| 2020-12-31 | $-427.15 | $1.57 | x |
| 2021-12-31 | $1264.99 | $1.57 | x |
| 2022-12-31 | $199.78 | $1.57 | x |
| 2023-12-31 | $302.49 | $1.57 | x |
| 2024-12-31 | $-5.67 | $1.57 | x |
| 2025-12-31 | $14.99 | $1.57 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Transcode Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -335.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 15.71x
- Recent ROE (-335.36%) is below the historical average (-255.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-403.04K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-497.46K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.00 Million |
| 2021 | -33.54% | 0.00% | 0.00x | 1.12x | $-8.88 Million |
| 2022 | -542.01% | 0.00% | 0.00x | 2.34x | $-17.89 Million |
| 2023 | -1130.30% | 0.00% | 0.00x | 3.15x | $-18.71 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.55 Million |
| 2025 | -335.36% | 0.00% | 0.00x | 15.71x | $-35.69 Million |
Industry Comparison
This section compares Transcode Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Transcode Therapeutics Inc (RNAZ) | $138.36 Million | 0.00% | 0.09x | $1.66 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastati… Read more